Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Bristol's early development lead exec Mike Burgess explains how the company is embracing adaptive trial design to rapidly test combinations of immuno-oncology drugs old and new, plus targeted agents.
You may also be interested in...
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.
With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”